Table 3

Logistic regression models for the association of serological variables with cognitive impairment in patients with SLE

Laboratory variableOR (95% CI)P value
Anti-dsDNA0.92 (0.36 to 2.37)0.87
Anti-chromatin0.63 (0.24 to 1.68)0.36
Anti-ribosomal PN/AN/A
Anti-Ro (60, 52)0.878 (0.33 to 2.33)0.79
Anti-La1.10 (0.28 to 4.37)0.89
Anti-Sm0.74 (0.21 to 2.63)0.64
Anti-RNP (A, 68)0.61 (0.21 to 1.73)0.35
Anticardiolipin1.16 (0.33 to 4.10)0.81
Anti-β2 glycoprotein I1.66 (0.36 to 7.77)0.52
LAC2.11 (0.69 to 6.39)0.19
Anticardiolipin or anti-β2 glycoprotein I or LAC1.62 (0.59 to 4.45)0.35
Anti-NR2 (peptide mix)1.23 (0.32 to 4.67)0.77
Anti-NR2 (protein mix)0.55 (0.13 to 2.32)0.42
Anti-GFAP1.73 (0.57 to 5.29)0.34
Anti-MPP10.45 (0.16 to 1.22)0.12
Low C34.37 (1.34 to 14.23)0.06
Low C41.13 (0.41 to 3.14)0.81
Elevated neurofilament light chains1.20 (0.41 to 3.51)0.74
NR2 protein mix MFINR2 peptide mix MFIMPP1 MFIGFAP MFI
Positive≥1000≥1000≥1000≥1000
  • dsDNA, double-stranded DNA; GFAP, glial fibrillar acidic protein; LAC, lupus anticoagulant; MFI, median fluorescence intensity; MPP1, M-phase phosphoprotein 1; N/A, not available due insufficient data for model; NR2, N-methyl-D-aspartic acid receptor 2; RNP, ribonucleoprotein.